TTrialPathMatch Me to Trials
← Back to trials
RecruitingMacular Edema Secondary to Inflammation

A Phase 3 Study to Evaluate the Efficacy and Safety of Intravitreal KSI-101 in Participants With Macular Edema Secondary to Inflammation (MESI) - PEAK

Eligible age

18+ yrs

Accepts

All genders

Locations

24 states

Healthy volunteers

No

See if you qualify for this study

Answer a few quick questions about your location and health. Takes about a minute.

Check my eligibility →

About this study

A Phase 3 Study to Evaluate the Efficacy and Safety of Intravitreal KSI-101 in Participants with Macular Edema Secondary to Inflammation (MESI)

Sponsor: Kodiak Sciences Inc

You may qualify if…

  • ✓ Macular Edema Secondary to Inflammation (MESI) with a central subfield thickness (CST) of ≥400 microns on SD-OCT in Study Eye.
  • ✓ Definitive presence of Intraretinal Fluid and/or Subretinal Fluid on SD-OCT in the Study Eye.
  • ✓ BCVA ETDRS score of ≥25 and ≤70 letters (between 20/40 and 20/320 Snellen equivalent) in the Study Eye.
  • ✓ Diagnosis of active or inactive non-infectious intraocular inflammation, acute or chronic in the Study Eye.

You may not qualify if…

  • ✕ Macular Edema in the Study Eye secondary to diabetic retinopathy, RVO, or wAMD.
  • ✕ Active or suspected ocular or periocular infection in either eye.
  • ✕ Any history of or active occlusive retinal vasculitis in either eye.

Where it's recruiting

Arizona

Phoenix · Scottsdale

California

Bakersfield · Glendale · La Jolla · Los Angeles …

Colorado

Denver

Connecticut

Greenwich · Manchester · Waterford

Florida

Altamonte Springs · Fort Lauderdale · St. Petersburg

Illinois

Elmhurst

Indiana

Carmel

Maryland

Hagerstown

Minnesota

Saint Louis Park

Missouri

St Louis

New Jersey

Palisades Park

Source: ClinicalTrials.gov · NCT06990399 · last updated 2026-05-18

A Phase 3 Study to Evaluate the Efficacy and Safety of Intravitreal KS · TrialPath